Vistagen Therapeutics (VTGN) Other Accumulated Expenses (2016 - 2023)
Vistagen Therapeutics (VTGN) posted Other Accumulated Expenses of $10000.0 for Q2 2023, up 733.33% sequentially from $1200.0 in Q3 2022, and up 85.19% YoY from $5400.0 in Q2 2022.
Vistagen Therapeutics (VTGN) Other Accumulated Expenses (2016 - 2023) Analysis & Trends
Vistagen Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $10000.0 in Q2 2023.
- Quarterly Other Accumulated Expenses rose 85.19% year-over-year to $10000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $10000.0 (up 85.19% YoY) and the FY2022 annual result came in at $32700.0, up 17.63% from the prior year.
- Other Accumulated Expenses climbed to $10000.0 in Q2 2023 per VTGN's latest filing, from $1200.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $62600.0 in Q3 2021 and troughed at $1200.0 in Q3 2022.
- A 5-year average of $16750.0 and a median of $8950.0 in 2019 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses surged 281.71% in 2021, then sank 98.08% in 2022.
- Over 5 years, Other Accumulated Expenses stood at $7900.0 in 2019, then sank by 30.38% to $5500.0 in 2020, then surged by 1038.18% to $62600.0 in 2021, then tumbled by 98.08% to $1200.0 in 2022, then jumped by 733.33% to $10000.0 in 2023.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $10000.0, $1200.0, and $5400.0 for Q2 2023, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10,000.00 |
| Sep 30, 2022 | 1,200.00 |
| Jun 30, 2022 | 5,400.00 |
| Mar 31, 2022 | 32,700.00 |
| Sep 30, 2021 | 62,600.00 |
| Mar 31, 2021 | 27,800.00 |
| Dec 31, 2020 | 5,500.00 |
| Sep 30, 2020 | 16,400.00 |
| Jun 30, 2020 | 20,700.00 |
| Mar 31, 2020 | 22,700.00 |
| Dec 31, 2019 | 7,900.00 |
| Sep 30, 2019 | 7,200.00 |
| Jun 30, 2019 | 7,700.00 |
| Mar 31, 2019 | 6,700.00 |
| Dec 31, 2018 | 8,800.00 |
| Sep 30, 2018 | 5,500.00 |
| Jun 30, 2018 | 3,500.00 |
| Mar 31, 2018 | 2,700.00 |
| Dec 31, 2017 | 3,100.00 |
| Sep 30, 2017 | 10,000.00 |